Background Valproic acid, a histone deacetylase inhibitor, has beneficial effects in the setting of cancer, neurologic diseases, and traumatic injuries. In animal models of traumatic injury, a single dose of valproic acid has been shown to reduce mortality. The purpose of this trial was to determine the maximum tolerated single dose of intravenous valproic acid in healthy humans. Methods A double-blinded, placebo-controlled, dose-escalation trial design was used to identify dose-limiting toxicities in healthy subjects who received a single dose of intravenous valproic acid. Patients were monitored for adverse events and data were collected for pharmacokinetic, pharmacodynamic, and safety profiling of valproic acid. Results Fifty-nine healthy subjects (mean 30 ± 12 years) were enrolled. Forty-four subjects received valproic acid in doses from 15 to 150 mg/kg. The most common adverse events were hypoacusis (n = 19), chills (n = 18), and headache (n = 16). The maximum tolerated dose was 140 mg/kg. Dose-limiting toxicities included headache and nausea lasting longer than 12 h. No drug-related abnormalities were seen in other safety measures including laboratory tests, hemodynamic parameters, cardiac rhythm monitoring, and cognitive testing. A two-compartment model was predictive of valproic acid concentration-time profiles, with a strong correlation (R 2 = 0.56) observed between the number of reported adverse events and the dose level. Conclusions The maximum tolerated dose of intravenous valproic acid in healthy subjects is 140 mg/kg. This is significantly higher than the previously established maximum tolerated dose of 60-75 mg/kg. Next, the safety and tolerability of high-dose valproic acid will be tested in trauma patients in hemorrhagic shock. ClinicalTrials.gov Identifier: NCT01951560
Introduction
The US Food and Drug Administration (FDA) originally approved valproic acid (VPA) in 1978 for the treatment of epilepsy, an indication for which it is routinely used today. Evidence supports multiple mechanisms of action that may explain the anti-epileptic effects of VPA, including gamma-aminobutyric acid-ergic potentiation, glutamate and N-methyl-D-aspartate receptor inhibition, and blockage of voltage-gated sodium channels [1] . More recently, VPA has been identified as a non-selective histone deacetylase (HDAC) inhibitor [2] . Acetylation and deacetylation of histone proteins play central roles in the regulation of gene expression. By increasing histone protein acetylation, HDAC inhibitors relax chromatin conformation and enhance transcriptional activity [3] . Histone deacetylase inhibitors have also been shown to increase acetylation of non-histone proteins, the regulatory scope of which has been compared to other major post-translational modifications such as phosphorylation [4] .
As the scientific community's understanding of acetylation expands, agents that modify the acetylome have garnered more attention. Intensive research is now being conducted in the fields of oncology, neurology, and rheumatology, where VPA and other HDAC inhibitors have shown promise treating conditions such as leukemia, multiple sclerosis, and arthritis [5] [6] [7] . Our group has focused on the use of VPA in the setting of traumatic injuries, where preclinical studies have demonstrated improved outcomes both in vitro and in vivo [8] . The use of VPA to treat injury is a novel concept and represents an opportunity to improve outcomes in trauma, which is the number one cause of death and disability in people aged under 46 years in USA [9] . In this population, hemorrhage has been identified as the leading cause of preventable death. Our ability to treat hemorrhage, however, is limited, and requires rapid access to surgical care and blood products [10] [11] [12] . In large animal models of traumatic injury and hemorrhage, we have shown that intravenously administered VPA can serve as a bridge to definitive care. In swine subjected to hemorrhage and polytrauma, treatment with VPA decreased mortality by 50% and did so in the absence of isotonic fluid resuscitation [13, 14] . Improved outcomes have also been validated in more complex models of injury, including those combining hemorrhagic shock with sepsis [15] [16] [17] or traumatic brain injury (TBI) [18] [19] [20] .
In preclinical studies of traumatic injury, intravenous VPA has been administered as a single dose from 150 to 400 mg/kg administered over a period of 90-180 min. Based on simple allometry, the estimated human equivalent dose is 140-360 mg/kg. Clinical pharmacokinetic studies of VPA at doses less than 60 mg/kg suggest a volume of distribution of 0.1-0.4 L/kg and a plasma elimination half-life of 10-16 h [21] . Studies evaluating the pharmacokinetics of VPA at doses higher than previously established maximum tolerated values of 60 and 75 mg/kg have not been performed [22, 23] . We therefore conducted an FDA-approved, phase I, single-dose, doubleblind, placebo-controlled trial to determine the safety and tolerability of higher than previously studied intravenous VPA doses in healthy human subjects. Data generated from pharmacokinetic, pharmacodynamic, and safety profile testing were used to determine the maximum tolerated dose (MTD) of VPA for use in a phase Ib trial studying patients in hemorrhagic shock. This is the first study to evaluate high-dose intravenous VPA in healthy adult volunteers, and provides safety and pharmacokinetic insights that will serve to benefit investigators seeking to evaluate this compound for a broad range of indications.
Methods

Patients
Healthy male and female subjects aged 18-65 years and with body mass indexes between 18 and 30 kg/m 2 were eligible for the study. Medical history, physical examination, electrocardiogram (ECG), and routine laboratory tests (blood chemistry, hematology, and urinalysis) in addition to hepatitis B and C and human immunodeficiency virus screening were performed prior to enrollment to rule out any clinically significant medical conditions. Female subjects were required to be surgically sterilized or postmenopausal. Pregnancy was ruled out with a serum pregnancy test. Major exclusion criteria included: use of prescription or non-prescription drugs, herbs, or dietary supplements within 14 days of the first dose of study medication; abstinence of caffeine from day -1 to day 4; any history of VPA use; current alcohol, tobacco, or illicit drug use or past alcohol or illicit drug abuse; hypertension [resting blood pressure[140 (systolic) or [90 (diastolic) on two evaluations at least 10 min apart]; vaccination, treatment with an investigational drug, or blood donation within 30 days of the first dose of the study medication; febrile illness within 5 days of the first dose of the study medication; inadequate venous access; or inability to be confined to the clinical research facility as required by the protocol. For a detailed explanation of eligibility criteria, see the complete study protocol in the Electronic Supplementary Material.
Study Design
Valproic acid was studied using a double-blinded, placebocontrolled, single dose-escalation trial design. In each eight-person cohort, subjects were randomized 3:1 to receive one dose of intravenous VPA or placebo infused over a period of 60 min. Patients were monitored for adverse events (AEs) and blood was drawn at timed intervals to evaluate the pharmacokinetic, pharmacodynamic, and safety profile of VPA. Valproic acid dosing was based on the manufacturer's recommendations and previous clinical trials. The formulation of VPA used was Depacon Ò , the sodium salt of VPA (sodium 2-propylpentanoate; AbbVie, Chicago, IL, USA). As per the manufacturer's recommendations, the starting dose of VPA for the treatment of seizures is 15 mg/kg/day and the maximum dose is 60 mg/kg/day. A dose-escalation trial in which cancer patients received a single dose of intravenous VPA daily for 5 days found the MTD to be 60 mg/kg/day [22] . The starting dose for this single-administration study in healthy subjects was 15 mg/kg, with subsequent doses increasing to 30, 60, 90, 120, 130, 140, and 150 mg/kg. Valproic acid (100 mg/mL) was diluted with saline to a total volume of 300 mL and prepared within 24 h of study drug administration. The placebo consisted of normal saline and was identical in appearance to the study drug. All patients, clinicians, and data collectors were blinded to subject assignments for the duration of the study.
Toxicity was monitored and documented using the Medical Dictionary for Regulatory Activities [24] . Adverse events were categorized as mild, moderate, or severe based on predefined definitions and were determined based on subject symptoms, physical examination findings, vital signs, clinical laboratory parameters, ECG, and Abbreviated Mental Test (AMT) [25] and Mini-Mental State Examination (MMSE) [26] scores. Complete definitions of mild, moderate, and severe AEs are described in the complete study protocol (Electronic Supplementary Material). Briefly, a moderate AE was defined as an event of sufficient severity to require more than one dose of treatment to alleviate symptoms and/or an event that takes longer than 12 h to resolve. Additional physiologic and biochemical criteria are included in the study protocol. A serious AE was defined as an event that results in death, life-threatening illness, hospitalization, persistent or significant disability, or a congenital anomaly. Study investigators determined the relationship of AEs to VPA, which were definitely, probably, possibly, unlikely, or definitely not related to the study drug. Dose-limiting toxicities (DLTs) were defined as any definite, probable, or possible drug-related moderate or higher AE. Dose escalation occurred when fewer than two subjects in any six-subject cohort experienced DLTs. The study's safety review committee and independent data safety monitoring board approved each dose escalation. Depending on the results of preceding dose groups, VPA dosing could be adjusted in the event that a DLT was observed in two or more subjects in any cohort. Ultimately, DLTs were identified in the 150-mg/kg cohort. As this represented a 20% increase in dose from 120 to 150 mg/kg, we elected to evaluate the tolerability of VPA at intermittent dosages (130 and 140 mg/kg). This decision was reviewed and approved by the FDA, institutional review board, safety review committee, and data safety monitoring board.
Subjects were admitted to the clinical research unit for 5 days (1 day prior to drug administration and 4 days after) and returned for a final follow-up 14 ± 2 days after discharge. While admitted, vital signs and a physical examination were performed at regular intervals. Cognitive testing using the AMT and MMSE were performed immediately before drug administration and at 1, 4, 12, and 24 h after. Scores of \7 on the AMT and \26 on the MMSE were considered moderate AEs. Pharmacokinetic and clinical safety laboratory tests, including complete blood count, comprehensive metabolic panel, magnesium, phosphorus, lipase, amylase, prothrombin time, and partial thromboplastin time, were drawn immediately before drug infusion and at 55 min, and 2, 4, 8, 16, 24 36, 60, and 72 h after the initiation of drug infusion. Pharmacodynamic laboratory tests were drawn immediately before drug infusion and at 2, 4, 8, 16, 24, 48, and 72 h after the initiation of drug infusion. Pharmacodynamic evaluation was specific to the mechanism of action of VPA as an HDAC inhibitor and included determination of histone 3 acetylation using Western blot and evaluation of differentially expressed proteins in peripheral blood mononuclear cells using protein mass spectrometry. Initial pharmacodynamic results are published separately [27] .
Bioanalysis
Plasma samples were assayed for VPA using a liquid chromatography mass spectrometry method. An ABI-3200 Qtrap mass spectrometer (Applied Biosystems, Foster City, California, USA) with electrospray ionization probe was interfaced with an Agilent 1200 series high-performance liquid chromatography system for sample analysis (Santa Clara, California, USA). The Analyst Software Version 1.4.2 package supplied by Applied Biosystems (MDS SCIEX, Foster City, Califorrnia, USA) was used to control the liquid chromatography tandem mass spectrometry system, as well as for data acquisition and processing. Valproic acid and benzoic acid (internal standard) were separated on a Xbridge C-18 column, 50 mm 9 4.6 mm ID, 3.5 um (Waters Co., Milford, CT, USA) under isocratic conditions at a flow rate of 1000 lL/min. The mobile phase consisted of H 2 O:acetonitrile in a ratio of 20:80 (v/v) with 5 mM ammonium formate at pH 9 adjusted with ammonium hydroxide. The mass spectrometer was operated in the negative mode with selected reaction monitoring for the analytes. The gas temperature was 700°C with an ion spray voltage of 4500 V, declustering potential of 33, curtain gas of 45, and collision energy of 11. The mass transitions were monitored at m/z 143.0 ? 143.0 for VPA and m/z 121 ? 77 for the internal standard. A plasma sample (200 lL) was pipetted into a micro-centrifuge tube and then 20 lL of internal standard working solution (500 lg/ mL) and 200 lL of 1%formic acid (v/v) were added. The mixture was vortex mixed for 30 s and loaded onto a 96-well OASIS HLB SPE cartridge (60 mg; Waters Co.), which had been conditioned by washing with acetonitrile (1 mL) followed by water (2 mL). The OASIS cartridge was rinsed with water (2 mL) followed by 10% methanol (1 mL), and then eluted with 80% acetonitrile (1 mL). Then, 5 lL of elutant was transferred into a high-performance liquid chromatography vial for injection and injected into the liquid chromatography/mass spectrometry system for analysis. The peak area of endogenous components eluted at the retention times of VPA and the internal standard in control plasma was less than 10% of that at the lower limit of quantification (5 lg/mL).
Ratios of VPA peak areas to the internal standard peak areas were calculated. The calibration curve was constructed using the peak area ratios of the eight calibration standards (from 5 to 1000 lg/mL) and the best fit was determined by a method of least squares using a weighting factor of 1/concentration 2 . Valproic acid plasma concentration below 5 lg/mL was reported as the low limit of quantification and used as zero in the calculation of mean concentrations and the standard deviations.
Pharmacokinetic Analyses
The pharmacokinetic data analyses were performed in three stages, including exploratory analyses of concentration-time profiles, non-compartmental analyses, and population pharmacokinetic analyses. Concentration-time profiles were visualized using STATA/IC Version 14 (Stata Corp, College Station, TX, USA). Non-compartmental analysis was performed using Phoenix/WINNONLIN 6.3 (Pharsight, St. Louis, MO, USA) to derive initial pharmacokinetic parameter estimates for population analyses. Population pharmacokinetic analyses were performed using PMetrics Ò Version 1.5.0 (LAPK, Los Angeles, CA, USA) with an iterated two-stage Bayesian algorithm evoked through R. One-, two-, and three-compartment linear models with zero-order rates of input were tested. This was followed by a non-linear model such as Michaelis-Menten and a parallel linear/Michaelis-Menten model. Model discrimination was performed based on goodness-of-fit plots of the population observed vs. predicted, individual observed vs. predicted, comparisons of inter-individual variability, e-shrinkage, the Akaike Information Criterion, and visual predictive check. The maximum plasma concentration was the plasma concentration at the end of a 1-h infusion. The final model was used to generate empiric Bayesian estimates of pharmacokinetic parameters, area under the plasma concentration-time curve (AUC) from time zero to 24 h, AUC from time zero to infinity (AUC inf ), and plasma concentration at 24 hours (C 24 ).
Pharmacodynamic Safety Analyses
Assessment of exposure-safety relationships was based on repeated measured values and subject-reported AEs. The variables analyzed included vital signs (heart rate, temperature, blood pressure, and respiratory rate), laboratory parameters (hematology, chemistry), organ-specific laboratory measures (liver transaminases, pancreatic enzymes), and coagulation markers over time. A longitudinal approach using multi-level regression analysis was used to compare the effects of the dose level on temporal changes in continuous measured values. The subject-reported AEs were binary coded into six groups that included the presence or absence of neurological changes, hearing changes, visual changes, nausea, vomiting, and chills. The effect of the VPA dose on these AEs was tested using Fisher's exact test to identify significant relationships (p \ 0.05). Classification and auto-regression tree analysis were used to identify breakpoints for dose (mg/kg), dose (mg), C max , and AUC inf associated with subject-reported AEs. All statistical analyses were executed using STATA/IC Version 14.
Study Approval
The study was approved by the University of Michigan Institutional Review Board and conducted under a FDA investigational new drug application (113,010). Participants gave written informed consent prior to inclusion in the study.
Results
Safety
Fifty-nine healthy subjects (five were female, mean age 30.2 ± 11.7 years, range 18-60 years) were enrolled for a single predefined dose of VPA (Fig. 1 ). Subjects were Caucasian (n = 47, 80%), African-American (n = 10, 17%), and Asian (n = 2, 3%). Forty-four subjects (75%) received VPA and 15 received placebo (25%). No DLTs or serious AEs were observed in subjects enrolled in dose cohorts up to 120 mg/kg (15, 30, 60, 90 , 120 mg/kg). Two of three subjects in the 150-mg/kg dose cohort experienced at least one moderate AE. These included headache and nausea lasting longer than 12 h that did not resolve following administration of acetaminophen or ondasetron, respectively. Both subjects' symptoms resolved without further intervention and within 24 h of VPA infusion.
Given these findings, an FDA-and institutional review board-approved amendment was made to the protocol to allow for de-escalation of dosing to better determine the MTD of VPA. With the guidance of the safety review committee and data safety monitoring board, doses of 130 and 140 mg/kg were evaluated. Ultimately, the MTD single intravenous dose of VPA was defined as 140 mg/kg. A total of 127 AEs were observed in all cohorts and are summarized in Table 1 . The most common AEs included hypoacusis (n = 19 subjects), chills (n = 18), headache (n = 16), tinnitus (n = 15), and nausea (n = 10), all of which were determined ''likely'' related to the study drug. Overall, 43 of 59 subjects (73%) experienced at least one AE. Many subjects developed more than one AE. No significant drug-related abnormalities were seen in other safety measures, including clinical safety laboratory tests (complete blood count, comprehensive metabolic panel, magnesium, phosphorus, lipase, amylase, prothrombin time, and partial thromboplastin time), ECG parameters, and cognitive testing (AMT and MMSE). There was no evidence of complications related to the black-box warnings for VPA (hepatotoxicity, pancreatitis, and teratogenicity). All subjects completed the study procedures as per protocol guidelines (Electronic Supplementary Material).
Pharmacokinetic Analysis
The mean concentration-time profiles are illustrated in Fig. 2 based on the dose level. The 140-mg/kg dose cohort had the highest concentrations with a mean maximum plasma concentration (C max ) of 1271 mg/L. Evaluation of the logarithm-transformed concentration-time data revealed that the profile declined in a biphasic manner. Consistent with this observation, a two-compartment model was identified as the optimal model predictive of VPA concentration-time profiles using the lowest Akaike predicted plots for the population and individual models are illustrated in the Electronic Supplementary Material, which shows the two-compartment model to be optimal (Fig. S1 ) and supported by the visual predictive check (Fig. S2) . A summary of parameters generated using alternate linear pharmacokinetic models is detailed in Table 2 . The mean volume of the central compartment was estimated to be 11 L with a mean VPA clearance of 1.16 L/h. A summary of the final model generated by individual estimates of systemic exposure is provided in Table 3 . As shown, trends toward a shortening half-life were observed at higher dosing levels based on a milligram/kilogram basis. Non-linear models of clearance were tested but did not improve the model fit relative to the two-compartment linear model. Differences in exposure in the higher dosing groups could, however, be explained by actual differences in body weight in dosing groups. For example, the concentrations observed in the 150-mg/kg group were lower than the 140-mg/kg group owing to a lower median body weight of 64 and 78 kg, respectively, leading to lower absolute doses. Figure 3 illustrates good relationships between the observed AUC inf , C max values, and absolute doses relative to dose (based on weight). Consistent with these findings, the inter-individual variability in pharmacokinetic parameters such as clearance and volume of the central compartment was not explained by body weight alone (Fig. S3) . Regression of AUC inf to VPA absolute dose (Fig. 2b) shows a proportionate relationship (slope = 0.927, near unity with no constant), whereas the administered dose nearly approximates the AUC inf . Similarly, regression of C max to VPA absolute dose (Fig. 2d) shows a proportionate relationship (slope = 0.0847, with no constant), whereas one eleventh of the administered dose (consistent with the volume of the central compartment estimate) approximates the C max .
Pharmacodynamic Safety Analysis
Comparisons of continuous measured variables over time demonstrated no significant relationship to the dose level except for heart rate. A transient elevation in the heart rate was observed near the end of VPA infusion (Fig. S4) and a significant correlation (p \ 0.001, R 2 = 0.35) was observed between tachycardia (C100 beats per minute) and the dose (Fig. S4) . The predicted change was approximately 1 beat per minute per 1000 mg of VPA above the predicted 10 beats per minute increase associated with the placebo. A strong correlation (R 2 = 0.56) was also observed between the number of subject-reported AEs and the dose level (Fig. 4) . Pharmacodynamic relationships between neurological changes, hearing changes, and chills as AEs were identified. A relative hazard ratio (RHR) of 1.54 was noted between C max values [256 mg/L compared with 0.56 for C max values B256 mg/L for neurologic AEs. These events included self-reports of headaches, light headedness, fogginess, dizziness, and feeling groggy. A similar RHR (1.79 vs. Data are presented as the number of self-reported adverse events in each dose category. Many subjects reported more than one adverse event Table 4 . As demonstrated, the risk for selected selfreported AEs is dose/exposure dependent.
Pharmacodynamic Effect Analysis
Pharmacodynamic evaluation was specific to the mechanism of action of VPA as an HDAC inhibitor and included the determination of histone 3 acetylation using western blot and protein mass spectrometry. Protein mass spectrometry was also used to evaluate differentially expressed proteins in peripheral blood mononuclear cells. These findings are published separately [27] .
Discussion
We have demonstrated that the maximum tolerated single intravenous dose of VPA in healthy humans is 140 mg/kg when infused over a 1-h period. This is significantly higher than both the maximum recommended oral dose (60 mg/ kg/day) and the previously established maximum intravenous dose (75 mg/kg) [23] . Adverse events were mild and no drug-related abnormalities were seen in other safety measures including clinical laboratory tests, ECG, and cognitive testing. Pharmacokinetic analysis demonstrated a two-compartment model predictive of VPA concentrationtime profiles, with a strong correlation observed between the number of reported AEs and the dose level. In this dose-escalation trial involving healthy humans, AEs related to VPA administration were mild. The most common side effects associated with treatment included hypoacusis, chills, headache, tinnitus, and nausea. Subjects tolerated these symptoms well, with all events resolving within 12 h of infusion. The DLTs experienced by two patients in the 150-mg/kg cohort included a headache lasting longer than 12 h that was not relieved with acetaminophen and nausea lasting longer than 12 h that was not relieved with odansetron. For both subjects, symptoms resolved without further intervention within 24 h of the infusion. These findings suggest that in the setting of cancer, traumatic injury, or other conditions in which VPA is used, the mild side effects associated with high-dose intravenous VPA are manageable. While neurovestibular side effects were prevalent, there was no significant difference between subjects' scores on the AMT and MMSE Table 2 Pharmacokinetic parameters based on one-, two-, and three-compartment models AIC Akaike Information Criterion,CL clearance, NA not applicable, Q 1 inter-compartmental clearance between the central and first peripheral compartment, Q 2 inter-compartmental clearance between the central and second peripheral compartment, V c volume of distribution of the central compartment, Vp 1 volume of distribution of the first peripheral compartment, Vp 2 volume of distribution of the second peripheral compartment Table 3 Weight, height, absolute dosage, and exposure parameters of dosing cohorts Values reported as mean (standard deviation); n = 6 per cohort, except for the 150-mg/kg cohort (n = 2) AUC inf area under the plasma concentration-time from time zero to infinity, AUC 24 area under the plasma concentration-time from time zero to 24 h, C max maximum plasma concentration, C 24 plasma concentration at 24 hours before and after VPA administration. Clinical safety laboratory tests were also unremarkable. Given the black-box warnings for hepatoxicity and pancreatitis, data related to organ function were collected. Liver function tests, amylase, and lipase were unchanged following a single dose of VPA, and no patients developed clinical evidence of organ injury. Vital signs were also monitored closely but were largely unaffected by VPA administration. The exception was a mildly elevated heart rate, which is discussed above. To date, two previous trials have evaluated high-dose intravenous VPA in human subjects. In patients with progressing solid tumors, Atmaca et al. [22] established 60 mg/kg/day to be the MTD of VPA. Daily doses of VPA were divided in half and administered intravenously twice daily over a 1-h period for 5 days. In another trial, Munster et al. [23] studied VPA in combination with epirubicin Predicted relative hazard ratio is listed in parenthesis C max maximum plasma concentration, AUC inf area under the plasma concentration-time from time zero to infinity, NA not applicable treatment for patients with advanced solid tumor malignancies. In the original study design, intravenous VPA was used as a loading dose before treatment with five oral doses every 12 h. As a result of DLTs in patients receiving loading doses of 60 or 75 mg/kg of intravenous VPA, the intravenous loading dose was changed to an orally administered dose. Once the transition was made to complete oral dosing, the MTD of VPA was determined to be 140 mg/kg [23] . DLTs in these studies included somnolence, confusion, and dizziness-findings that were also identified in our study population. In contrast to our study, subjects in these trials also developed hematologic disturbances (i.e., neutropenia), physiologic changes (i.e., fevers), and ECG changes (i.e., corrected QT prolongation), which we did not identify in healthy volunteers. Important differences between these trials and ours include the patient population studied, the method and dosing regimen by which VPA was administered, the plasma sampling schedule, and the fact that all patients included in this study were not currently taking any other pharmacologic agents. It is likely that these significant differences in study protocols contributed to the identified differences in VPA plasma concentrations between previously performed studies and our current trial. Although oral dosing can result in high serum concentrations of VPA, we sought to evaluate intravenously administered VPA. The rationale for this decision was related to our anticipated use of VPA in traumatized patients, who may not be able to have orally administered agents. While the package insert for Depacon Ò states that intravenous and oral administration of VPA are equivalent, we found that the peak serum concentrations of VPA in our study was significantly higher than those identified in patients given the same dose of oral VPA [140-mg/kg dose, intravenous dosing (current study): 1000-1250 lg/mL vs. oral dosing [23] : 300-400 lg/mL]. In addition, we were able to show that a two-compartment linear model adequately explains the concentration-time data across a 14-fold range of absolute doses (846-12,264 mg). This population model described 85.6% of the inter-individual variability without a covariate structure, implying that predictable exposure should be expected in future clinical trials involving high doses of VPA. However, we cannot be certain that this model is optimal because we did not measure unbound VPA concentrations. The saturable protein-binding profile of VPA should have supported the selection of an alternate non-linear model to explain the clearance of this agent. Post-hoc analyses comparing the AUC/dose ratio or clearance by dose group (mg/kg) did not reveal a clear pattern that could be explained by known models of saturable protein binding.
Despite this key limitation, we were able to identify pharmacodynamic breakpoints predictive of drug safety, and demonstrated a higher threshold for neurologic toxicities than previously established. In regard to VPA metabolism, intravenous VPA has a clearance value of approximately 1 L/h. This has practical implications for future dose selection, as an AUC breakpoint predictive of therapeutic effect will approximate the AUC. Prior work from investigators at the Kentucky poison control center provides additional insight into VPA toxicity. In this series, 133 patients with acute VPA ingestion and VPA serum concentrations [100 mg/L were evaluated [28] . The mean (range) C max VPA concentration was 378 (110-1840) mg/ L. Two patients had a fatal outcome, and a C max [850 mg/ L was found to be predictive of serious AEs such as coma and respiratory depression. However, these evaluated C max values were measurements taken on average 7.4 h after ingestion. As such, the true C max would be expected to be much higher, which would be more consistent with our findings.
Despite improved outcomes in large animal models of hemorrhage and TBI, the protective mechanism of action of VPA is not well understood. However, recent work from our laboratory has yielded exciting clues. As a part of this trial, peripheral blood mononuclear cells were collected from subjects for proteomic analysis. In total, 140 differentially expressed proteins were identified. Functional annotation revealed alterations in proteins related to cell death and survival, fatty acid metabolism, neurologic disorders, and cellular component organization. Full results from this analysis have been published separately [27] , and additional work is currently being conducted to better understand these findings.
We have also identified specific transcriptional programs in the central nervous system that are induced by VPA. Using a variety of sources, including published studies, public and commercial databases, and animal experiments, we found that VPA may be acting through regulatory pathways that enhance neurogenesis and reduce gliogenesis. Genes that encode transcription factors that specify neuronal cell fate, including MEF2D, MYT1L, NEUROD1, PAX6, and TBR1, and their target genes, are up-regulated by VPA. In fact, NEUROD1 has regulatory interactions with 38% of the genes regulated by VPA in a swine model of TBI and hemorrhagic shock. Valproic acid was also found to repress genes responsible for oligodendrogenesis, angiogenesis, and endothelial cell proliferation (unpublished data) [29] . In a separate study, we used immunofluoroscopy to show that VPA protects the integrity of the blood-brain barrier in swine subjected to TBI and hemorrhagic shock. Animals treated with VPA had increased expression of tight-junction-and basement membrane-associated proteins, including zona occludin-1, laminin, and claudin-5. Similar outcomes were achieved in vitro, where monolayers of endothelial cells subjected to anoxia and treated with VPA had significantly decreased permeability relative to anoxic controls [30] .
With such broad clinical application, the MTD of intravenous VPA is an important discovery. However, there are limitations to this trial. First, the majority of subjects in this study were young healthy male individuals. This is in part explained by the exclusion of women of childbearing age owing to the known teratogenicity of VPA. The pharmacokinetic and pharmacodynamic profiles of VPA may be altered in different patient populations. For this reason, the safety and tolerability of VPA is currently being evaluated in patients in hemorrhagic shock. Second, this study involved a single dose of intravenous VPA. For the majority of established clinical applications such as epilepsy and bipolar disorder, VPA is taken on a daily basis, by mouth, and at relatively low doses. Whether the effects of VPA are optimized following a single intravenous dose is not known. We are currently in the process of developing further large animal studies to determine the optimal dose, timing, and administration strategy (e.g., split dosing, multiple dosing) of VPA in the setting of trauma. Finally, a phase I trial such as this does not establish the efficacy of VPA treatment. This study represents phase Ia of a two-part phase I trial (NCT01951560). Phase II and III trials to determine whether VPA can improve outcomes in trauma patients have already been approved for funding by the US Department of Defense.
Conclusion
This study shows that a single intravenous dose of VPA as high as 140 mg/kg is well tolerated in healthy subjects. This is significantly higher than the previously established MTD and has important implications for the treatment of a variety of disease states, including hemorrhagic shock. While additional studies are needed to determine the efficacy of high-dose VPA, the pharmacokinetic model developed as part of this study will help guide the design of future clinical trials. 
